11/21
07:40 am
mrus
Merus (NASDAQ: MRUS) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $73.00 price target on the stock.
Low
Report
Merus (NASDAQ: MRUS) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $73.00 price target on the stock.
11/20
08:06 am
mrus
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $85.00 price target on the stock.
Medium
Report
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $85.00 price target on the stock.
11/6
04:13 pm
mrus
Merus to Present at Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Merus to Present at Upcoming Investor Conferences [Yahoo! Finance]
11/6
04:01 pm
mrus
Merus to Present at Upcoming Investor Conferences
Low
Report
Merus to Present at Upcoming Investor Conferences
11/5
06:30 am
mrus
Merus Receives FDA extension of PDUFA for zenocutuzumab
Low
Report
Merus Receives FDA extension of PDUFA for zenocutuzumab
11/1
08:15 am
mrus
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $85.00 price target on the stock.
Low
Report
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $85.00 price target on the stock.
11/1
08:15 am
mrus
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $85.00 price target on the stock.
Low
Report
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $85.00 price target on the stock.
10/31
08:08 am
mrus
Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update
Low
Report
Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update
10/24
07:16 am
mrus
Merus (NASDAQ: MRUS) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $72.00 price target on the stock.
Low
Report
Merus (NASDAQ: MRUS) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $72.00 price target on the stock.
10/17
09:21 am
mrus
Investing in Merus (NASDAQ:MRUS) five years ago would have delivered you a 227% gain [Yahoo! Finance]
Low
Report
Investing in Merus (NASDAQ:MRUS) five years ago would have delivered you a 227% gain [Yahoo! Finance]
10/1
01:17 pm
mrus
Merus (NASDAQ: MRUS) had its price target raised by analysts at Guggenheim from $93.00 to $111.00. They now have a "buy" rating on the stock.
Low
Report
Merus (NASDAQ: MRUS) had its price target raised by analysts at Guggenheim from $93.00 to $111.00. They now have a "buy" rating on the stock.
9/30
08:00 am
mrus
Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC
Medium
Report
Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC
9/18
10:23 am
mrus
TimesSquare Capital Management U.S. Small Cap Growth Strategy Established a Position in Merus N.V. (MRUS) [Yahoo! Finance]
Low
Report
TimesSquare Capital Management U.S. Small Cap Growth Strategy Established a Position in Merus N.V. (MRUS) [Yahoo! Finance]
9/17
09:00 am
mrus
Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024
Medium
Report
Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024
8/30
01:26 am
mrus
Merus NV (MRUS): Top ADR Stock According to Hedge Funds [Yahoo! Finance]
Low
Report
Merus NV (MRUS): Top ADR Stock According to Hedge Funds [Yahoo! Finance]
8/28
07:00 am
mrus
Foundation Medicine Collaborates With Merus to Advance Treatment Options in NRG1 Fusion-Driven Tumors Using Foundation Medicine’s RNA Platform
Low
Report
Foundation Medicine Collaborates With Merus to Advance Treatment Options in NRG1 Fusion-Driven Tumors Using Foundation Medicine’s RNA Platform